Invasive cribriform carcinoma of the breast

Last updated
Cribriform carcinoma of the breast
Other namesInvasive cribriform carcinoma
Breast CribriformCarcinoma HP SNP.jpg
Cribriform carcinoma of the breast showing a cribriform area
Specialty Oncology, Surgical oncology
Prognosis excellent

Invasive cribriform carcinoma of the breast (ICCB), also termed invasive cribriform carcinoma, is a rare type of breast cancer that accounts for 0.3% to 0.6% of all carcinomas (i.e. cancers that develop from epithelial cells) in the breast. [1] It originates in a lactiferous duct as opposed to the lobules that form the alveoli in the breasts' mammary glands (lobules make the milk which the ducts channel to the breast's nipple). ICCB was first described by Dixon and colleagues in 1983 as a tumor that on microscopic histopathological inspection had a cribriform pattern, [2] i.e. a tissue pattern consisting of numerous "Swiss cheese"-like open spaces and/or sieve-like small holes (see adjacent Figure). [3] The latest edition (2019) of the World Health Organization (2019) termed these lesions invasive cribriform carcinomas indicating that by definition they must have a component that invades out of their ducts of origin into adjacent tissues. In situ ductal cancers (i.e. cancers localized entirely within their tissues of origin) that have a cribriform histopathology are regarded as belonging to the group of ductal carcinoma in situ tumors. [4]

Contents

Rarely, cancers with the histopathological cribriform pattern develop in other organs such as the prostate gland (termed invasive cribriform prostate cancer or cribriform prostate cancer), [5] salivary gland (termed cribriform adenocarcinoma of salivary glands), [6] sweat glands (termed primary cutaneous cribriform apocrine carcinoma), [7] thyroid gland (termed cribriform-morular thyroid carcinoma), [8] colon (termed cribriform colon cancer), [9] [10] and lung (termed cribriform pattern in lung adenocarcinoma and considered to be a rare variant of acinar adenocrcinoma of the lung). [11] Here, the term invasive cribriform carcinoma of the breast rather than invasive cribriform carcinoma is used in order to clearly distinguish it from these other cribriform carcinomas.

ICCB, while clearly a cancerous tumor that occurs predominantly in older females and in rare cases males, has many favorable clinical and pathological features including a low rate of metastasizing to distant tissues and an excellent prognosis. [12] Earlier editions of the World Health Organization divided ICCB into two forms, the "pure" form (sometimes termed "classical"), i.e. ICCB tumors that had >90% cribriform areas, and the "mixed" form, i.e. ICCB tumors that had >50% cribriform areas with the remaining areas having a tubular histological pattern. [4] However, many earlier [1] [11] [13] [14] [15] [16] and more recent [3] [12] [17] studies have regarded mixed ICCB as consisting of >50% cribriform areas with the remaining areas containing tubular or certain other histopathological patterns. The latter definition of mixed ICCB is used here.

Presentation

Individuals presenting with ICCB in one large study were on average 61 years/old post-menopausal females and similarly aged males (average age 65.4 [17] ) with the males representing 1.7% of all cases. [12] However, individuals as young as 14 [18] and 18 [17] years have been diagnosed with the disease. ICCB tumors are small (i.e. 58%-75.4% less than 2-5 centimeters and 22%-38% more than 2-5 centimeters in largest diameters), asymptomatic masses first detected by palpation or screening methods such as mammography or medical ultrasound. Screening methods often (i.e. 32% of cases) detect areas of microcalcification (i.e. tiny deposits of calcium) in the masses. In a relatively small percentage of cases (e.g. 15.9 to 25.5% in most studies), the workup of these individuals finds that their tumor has metastasized (i.e. spread) to the lymph nodes in the nearby axilla (i.e. armpit). [1] Very rarely, individuals have presented with: an ulcerated skin lesions or inverted nipple, [18] [19] with recurrences at or near to the site were a ICCB tumor had been surgically removed, [13] or with metastases to distant tissues such as the vertebral bones. [12] [19]

Pathology

18S08891 tubular carcinoma x20a 18S08891 tubular carcinoma x20a.jpg
18S08891 tubular carcinoma x20a

The microscopic histopathology of ICCB tumors stained with hematoxylin and eosin shows cribriform areas covering more than 50% of the tumor with the remaining tumor areas showing tubular and/or other histopathological patterns. The cribriform areas consist of small-sized cells with amphophilic (i.e. taking up both the hematoxylin and eosin stains) cytoplasm, indistinct cell boundaries, and small-to-medium sized nuclei that are surrounded by a sharp nuclear membrane and contain finely stippled chromatin (i.e. DNA coated with protein). [17] Numerous open spaces and/or sieve-like small holes lie between these cells (see above photomicrograph) to give the lesions a Swiss cheese-like appearance. The spaces and holes may contain microcalcifications and/or mucins (i.e. high molecular weight, sugar-linked proteins normally produced and secreted by the mammary gland and found in milk). [3] The cells around these spaces and holes sometimes have "apical snouts", i.e. small protrusions on the side of the cells that faces the spaces and holes. [11] Tubular areas (see adjacent photomicrograph of a tubular carcinoma) consist of well-formed tubules lined with mostly normal appearing tubular cells. [17] [20] The other histopathological patterns that may occur in these tumor types include the pattern associated with invasive carcinoma of no special type [4] or in uncommon cases the pattern associated with mucinous carcinoma of the breast. [17] The invasive component of these tumors almost always has the cribriform histopathology pattern. [14] All of the tumor cells in ICCB are typically slow-growing as evidenced by their low mitotic index (i.e. the ratio of the number of dividing cells to the total number of tumor cells) or low levels of cellular Ki-67 protein (an index of cell proliferation). [14]

A Seer study of 750 individuals with pure or mixed ICCB reported that: a) 92.8% consisted of tumor cells that were scored well-differentiated (i.e. grade 1) or moderately well-differentiated (grade 2) (differentiation is the degree to which tumor cells resemble the non-cancerous cells in the tissue from which they derived) while 7.2% were scored poorly-differentiated (grade 3) or undifferentiated (grade 4) tumor cells; b) 76.1, 20.0, 2.6, and 1.3% of the cases had T1, T2, T3, and T4 tumors, respectively (increasing T numbers indicate increasing tumor size and/or invasion into adjacent tissues); c) 83.2, 13,6, 2.4. and 0.8% of all cases had tumors which metastasized respectively to 0 (i.e. no metastasis), 1, 2, or 3 nearby armpit lymph nodes; and d) 1.3% of all cases had metastasizes in distant tissues (the tissue sites were not identified). [12] In a study of 42 individuals, 16 (38.1%) had pure and 26 (61.9%) had mixed ICCB; there were no significant differences in age of presentation, tumor size, or tumor grade between pure and mixed ICCB; pure ICCB had 5 (31.5%) and mixed ICCB had 16 (61.5%) cases that were associated with lymph node metastases; and there were no cases that had distant tissue metastases. [17]

Immunohistochemistry

Microscopic inspection of immunostained (i.e. a method that uses specially prepared antibodies which attach to specific proteins so that they can be detected and quantified) ICCB tumor cells has shown that they express estrogen receptors in about 95.4% of cases, progesterone receptors in about 89.5% of cases, and the HER2/neu protein in about 3% of cases. [12] The estrogen and progesterone receptors and HER2/neu protein, when expressed by breast cancer tumor cells, are therapeutic targets for treating various forms of breast cancer including ICCB. [13] [14] ICCB tumors also typically have cells that express cytokeratin proteins but not myoepithelial marker proteins such as tumor protein 63, smooth muscle actin, [11] calponin, or CD10. [1]

Diagnosis

The diagnosis of ICCB tumors is based on the histopathology and immunohistochemistry of their hematoxylin and eosin-stained tissues, [13] particularly on identifying their predominantly cribriform structure and invasion into adjacent tissues. [1] [14] Immunostaining to define the expression pattern of the elements outlined in the above Immunohistochemistry section have also been used to support the diagnoses in less clear cases. [14] Adenoid cystic carcinoma and certain neuroendocrine tumors have been mistaken for ICCB tumors. Adenoid cystic carcinomas are distinguished form ICCB by having open spaces that are PAS diastase stain-positive and by the presence of tumor cells which express cKit but not estrogen and progesterone receptors; ICCB tumor open spaces are PAS diastase stain-negative and their tumor cells do not express cKit but do express estrogen and progesterone receptors. Neuroendocrine tumors with an invasive component (many of these tumors are non-invasive) are differentiated from ICCB tumors by their content of spindle-shaped cells, cells that resemble plasma cells, and large clear cells; these type of cells are typically not found in ICCB tumors. [11]

Treatment

Due to their relative rarity, standard treatment guidelines have not been formally identified or defined for ICCB tumors. Consequently, current treatments for these tumors are based on protocols used to treat invasive carcinoma of no special type. [17] (These treatments have not been strictly examined individually or compared between each other for their effectiveness in treating ICCB. [12] IBBC tumors do have the potential to metastasize to distant tissues if left untreated for a very long time period. [19] ) Virtually all patients (97.2% of the 760 cases) in the SEER review study were treated by surgical removal of their tumors. [12] This surgery has typically been either breast-conserving surgery or modified radical mastectomies. [17] Patients with ICCB may also receive adjuvant radiotherapy and/or chemotherapy. [17] In the Seer study, 52.2% were treated with radiotherapy and 22.1% with chemotherapy. [17] The chemotherapy regimens used to treat ICCB have included triple therapy with cyclophosphamide, epirubicin and fluorouracil, double therapy with docetaxel and epirubicin, [17] and triple therapy with cyclophosphamide, doxorubicin and fluorouracil. [19] In more recent studies, virtually all individuals have been treated with adjuvant hormonal therapy drugs, [17] such as letrozole or anastrozole (which block the metabolism of androgen to estrogens by the aromatase enzyme in non-gonad tissues and thereby reduce estrogen levels) or with tamoxifen (which acts indirectly to inhibit the estrogen receptor). [13] [19] Individuals with mixed ICCB have been treated with the more aggressive of these protocols than individuals with pure ICCB in some [17] but not all [1] studies. It has been suggested that pure ICCB tumors might be better treated with the more conservative strategies listed here. [21]

Prognosis

In the Seer study of 750 individuals with ICCB (pure and mixed types not distinguished), the overall survival rates (i.e. includes deaths due to ICCB and any other cause) at 3 and 5 years after initial treatment were 94.4% and 90.3%, respectively. Larger tumor size, presence of distant tissue metastases, higher tumor stages, older age (>67 years old), single or divorced marital status, and lack of progesterone receptors in tumor cells were associated with poorer prognoses while the presence of lymph node metastases did not significantly alter prognosis. [12] A more recent study of 42 patients with ICCB followed for an average of 88 months (range 15–106 months) reported that the median overall survival 5 years after treatment was 100% for both pure and mixed ICCB and the projected 10 year overall survival rate was 100% for pure and 90% for mixed ICCB. [17] Several other studies on small numbers of patients reported that pure and mixed ICCB individuals have 10 year overall survival rates of over 90%. [17] Recurrent ICCB has been successfully treated with surgical removal of the tumor plus chemotherapy [13] and ICCB with metastases to distant tissues has been successfully treated with surgical removal of the breast tumor, chemotherapy, radiotherapy, and long-term treatment with tamoxifen followed by letrozole. [19]

Related Research Articles

<span class="mw-page-title-main">Metastasis</span> Spread of a disease inside a body

Metastasis is a pathogenic agent's spread from an initial or primary site to a different or secondary site within the host's body; the term is typically used when referring to metastasis by a cancerous tumor. The newly pathological sites, then, are metastases (mets). It is generally distinguished from cancer invasion, which is the direct extension and penetration by cancer cells into neighboring tissues.

<span class="mw-page-title-main">Adenocarcinoma</span> Medical condition

Adenocarcinoma is a type of cancerous tumor that can occur in several parts of the body. It is defined as neoplasia of epithelial tissue that has glandular origin, glandular characteristics, or both. Adenocarcinomas are part of the larger grouping of carcinomas, but are also sometimes called by more precise terms omitting the word, where these exist. Thus invasive ductal carcinoma, the most common form of breast cancer, is adenocarcinoma but does not use the term in its name—however, esophageal adenocarcinoma does to distinguish it from the other common type of esophageal cancer, esophageal squamous cell carcinoma. Several of the most common forms of cancer are adenocarcinomas, and the various sorts of adenocarcinoma vary greatly in all their aspects, so that few useful generalizations can be made about them.

<span class="mw-page-title-main">Apocrine</span>

Apocrine is a term used to classify the mode of secretion of exocrine glands. In apocrine secretion, secretory cells accumulate material at their apical ends, and this material then buds off from the cells, forming extracellular vesicles. The secretory cells therefore lose part of their cytoplasm in the process of secretion.

<span class="mw-page-title-main">Invasive carcinoma of no special type</span> Medical condition

Invasive carcinoma of no special type, invasive breast carcinoma of no special type (IBC-NST), invasive ductal carcinoma (IDC), infiltrating ductal carcinoma (IDC) or invasive ductal carcinoma, not otherwise specified (NOS) is a disease. For international audiences this article will use "invasive carcinoma NST" because it is the preferred term of the World Health Organization (WHO).

<span class="mw-page-title-main">Gleason grading system</span> Score given to a prostate cancer based on its microscopic appearance

The Gleason grading system is used to help evaluate the prognosis of men with prostate cancer using samples from a prostate biopsy. Together with other parameters, it is incorporated into a strategy of prostate cancer staging which predicts prognosis and helps guide therapy. A Gleason score is given to prostate cancer based upon its microscopic appearance. Cancers with a higher Gleason score are more aggressive and have a worse prognosis. Pathological scores range from 2 to 10, with higher numbers indicating greater risks and higher mortality. The system is widely accepted and used for clinical decision making even as it is recognised that certain biomarkers, like ACP1 expression, might yield higher predictive value for future disease course.

<span class="mw-page-title-main">Ductal carcinoma in situ</span> Medical condition

Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive cancerous lesion of the breast. DCIS is classified as Stage 0. It rarely produces symptoms or a breast lump one can feel, typically being detected through screening mammography. It has been diagnosed in a significant percentage of men.

<span class="mw-page-title-main">Papillary hidradenoma</span> Medical condition

A papillary hidradenoma, also termed hidradenoma papilliferum or mammary-like gland adenoma of the vulva, is a rare, but nonetheless most common benign tumor that occurs in and between anal and genital regions of females. These hidradenomas are sharply circumscribed, nodular tumors that usually develop in women's anogenital area but uncommonly occur in other sites in women and men. Papillary hidradenomas that develop outside of the anogenital region are termed ecctopic papillary hidradenomas or ectopic hidradenoma papilliferums.

Breast cancer classification divides breast cancer into categories according to different schemes criteria and serving a different purpose. The major categories are the histopathological type, the grade of the tumor, the stage of the tumor, and the expression of proteins and genes. As knowledge of cancer cell biology develops these classifications are updated.

<span class="mw-page-title-main">Male breast cancer</span> Medical condition

Male breast cancer (MBC) is a cancer in males that originates in their breasts. Males account for less than 1% of new breast cancers with about 20,000 new cases being diagnosed worldwide every year. Its incidence rates in males vs. females are, respectively, 0.4 and 66.7 per 100,000 person-years. The worldwide incidences of male as well as female breast cancers have been increasing over the last few decades. Currently, one of every 800 men are estimated to develop this cancer during their lifetimes.

<span class="mw-page-title-main">Metastatic breast cancer</span> Type of cancer

Metastatic breast cancer, also referred to as metastases, advanced breast cancer, secondary tumors, secondaries or stage IV breast cancer, is a stage of breast cancer where the breast cancer cells have spread to distant sites beyond the axillary lymph nodes. There is no cure for metastatic breast cancer; there is no stage after IV.

<span class="mw-page-title-main">Poroma</span>

Poromas are rare, benign, cutaneous adnexal tumors. Cutaneous adnexal tumors are a group of skin tumors consisting of tissues that have differentiated towards one or more of the four primary adnexal structures found in normal skin: hair follicles, sebaceous sweat glands, apocrine sweat glands, and eccrine sweat glands. Poromas are eccrine or apocrine sweat gland tumors derived from the cells in the terminal portion of these glands' ducts. This part of the sweat gland duct is termed the acrosyringium and had led to grouping poromas in the acrospiroma class of skin tumors. Here, poromas are regarded as distinct sweat gland tumors that differ from other sweat gland tumors by their characteristic clinical presentations, microscopic histopathology, and the genetic mutations that their neoplastic cells have recently been found to carry.

Porocarcinoma (PCA) is a rare form of skin cancer that develops in eccrine sweat glands, i.e. the body's widely distributed major type of sweat glands, as opposed to the apocrine sweat glands which are located primarily in the armpits and perineal area. This cancer typically develops in individuals as a single cutaneous tumor in the intraepidermal spiral part of these sweat glands' ducts at or near to where they open on the skin's surface. PCA tumors are classified as one form of the cutaneous adnexal tumors; in a study of 2,205 cases, PCA was the most common (11.8%) form of these tumors.

<span class="mw-page-title-main">Spiradenoma</span> Medical condition

Spiradenomas (SA) are rare, benign cutaneous adnexal tumors that may progress to become their malignant counterparts, i.e. spiradenocarcinomas (SAC). Cutaneous adnexal tumors are a group of skin tumors consisting of tissues that have differentiated towards one of the four primary adnexal structures found in normal skin: hair follicles, sebaceous sweat glands, apocrine sweat glands, and eccrine sweat glands. SA and SAC tumors were regarded as eccrine gland tumors and termed eccrine spiradenomas and eccrine spiradenocarcinomas, respectively. However, more recent studies have found them to be hair follicle tumors and commonly term them spiradenomas and spiradenocarcinomas, respectively. Further confusing the situation, SA-like and SAC-like tumors are also 1) manifestations of the inherited disorder, CYLD cutaneous syndrome (CCS), and 2) have repeatedly been confused with an entirely different tumor, adenoid cystic carcinomas of the salivary gland. Here, SA and SAC are strictly defined as sporadic hair follicle tumors that do not include the hereditary CCS spiradenomas and heridtary spiradenocarcinoms of CCS or the adenoid cystic carcinomas.

Mammary analogue secretory carcinoma (MASC), also termed MASCSG, is a salivary gland neoplasm. It is a secretory carcinoma which shares the microscopic pathologic features with other types of secretory carcinomas including mammary secretory carcinoma, secretory carcinoma of the skin, and salivary gland–type carcinoma of the thyroid. MASCSG was first described by Skálová et al. in 2010. The authors of this report found a chromosome translocation in certain salivary gland tumors, i.e. a (12;15)(p13;q25) fusion gene mutation. The other secretory carcinoma types carry this fusion gene.

Papillomatosis of the breast (PB) is a rare, benign, epitheliosis-like lesion, i.e. an overgrowth of the cells lining the ducts of glands that resembles a papilla or nipple-like nodule/tumor. PB tumors develop in the apocrine glands of the breast. PB is also termed juvenile papillomatosis because of its frequent occurrence in younger women and Swiss cheese disease because of its microscopic appearance. Rarely, PB has also been diagnosed in very young, adolescent, and adult males.

A histopathologic diagnosis of prostate cancer is the discernment of whether there is a cancer in the prostate, as well as specifying any subdiagnosis of prostate cancer if possible. The histopathologic subdiagnosis of prostate cancer has implications for the possibility and methodology of any subsequent Gleason scoring. The most common histopathological subdiagnosis of prostate cancer is acinar adenocarcinoma, constituting 93% of prostate cancers. The most common form of acinar adenocarcinoma, in turn, is "adenocarcinoma, not otherwise specified", also termed conventional, or usual acinar adenocarcinoma.

Mammary secretory carcinoma (MSC), also termed secretory carcinoma of the breast, is a rare form of the breast cancers. MSC usually affects women but in a significant percentage of cases also occurs in men and children. Indeed, McDvitt and Stewart first described MSC in 1966 and termed it juvenile breast carcinoma because an increased number of cases were at that time diagnosed in juvenile females. MSC is the most common form of breast cancer in children, representing 80% of childhood breast cancers, although it accounts for less than 0.15% of all breast cancers.

CYLD cutaneous syndrome (CCS) is the recently designated term for three rare inherited cutaneous adnexal tumor syndromes: multiple familial trichoepithelioma (MFT1), Brooke–Spiegler syndrome (BSS), and familial cylindromatosis (FC). Cutaneous adnexal tumors are a large group of skin tumors that consist of tissues that have differentiated towards one of the four primary adnexal structures found in normal skin: hair follicles, sebaceous sweat glands, apocrine sweat glands, and eccrine sweat glands. CCS tumors are hair follicle tumors.

Papillary carcinomas of the breast (PCB), also termed malignant papillary carcinomas of the breast, are rare forms of the breast cancers. The World Health Organization (2019) classified papillary neoplasms of the breast into 5 types: intraductal papilloma, papillary ductal carcinoma in situ (PDCIS), encapsulated papillary carcinoma (EPC), solid-papillary carcinoma (SPC), and invasive papillary carcinoma (IPC). The latter four carcinomas are considered here; intraductal papilloma is a benign neoplasm. The World Health Organization regarded solid papillary carcinoma as having two subtypes: in situ and invasive SPC.

<span class="mw-page-title-main">Pure apocrine carcinoma of the breast</span> Medical condition

Pure apocrine carcinoma of the breast (PACB) is a rare carcinoma derived from the epithelial cells in the lactiferous ducts of the mammary gland. The mammary gland is an apocrine gland. Its lactiferous ducts have two layers of epithelial cells, a luminal layer which faces the duct's lumen and a basal layer which lies beneath the luminal layer. There are at least 4 subtypes of epithelial cells in these ducts: luminal progenitor cells and luminal mature cells which reside in the luminal layer and mammary stem cells and basal cells which reside in the basal layer. Examination of the genes expressed in PACB cancer cells indicate that most of these tumors consist of cells derived from luminal cells but a minority of these tumors consist of cells derived from basal cells.

References

  1. 1 2 3 4 5 6 Mo CH, Ackbarkhan Z, Gu YY, Chen G, Pang YY, Dang YW, Feng ZB (2017). "Invasive cribriform carcinoma of the breast: a clinicopathological analysis of 12 cases with review of literature". International Journal of Clinical and Experimental Pathology. 10 (9): 9917–9924. PMC   6965980 . PMID   31966881.
  2. ↑ Page DL, Dixon JM, Anderson TJ, Lee D, Stewart HJ (July 1983). "Invasive cribriform carcinoma of the breast". Histopathology. 7 (4): 525–36. doi:10.1111/j.1365-2559.1983.tb02265.x. PMID   6884999. S2CID   6585654.
  3. 1 2 3 Erber R, Hartmann A (August 2020). "Histology of Luminal Breast Cancer". Breast Care (Basel, Switzerland). 15 (4): 327–336. doi:10.1159/000509025. PMC   7490665 . PMID   32982642.
  4. 1 2 3 Cserni G (March 2020). "Histological type and typing of breast carcinomas and the WHO classification changes over time". Pathologica. 112 (1): 25–41. doi:10.32074/1591-951X-1-20. PMC   8138497 . PMID   32202537.
  5. ↑ Iczkowski KA, van Leenders GJ, Tarima S, Wu R, Van der Kwast T, Berney DM, Evans AJ, Wheeler TM, Ro JY, Samaratunga H, Delahunt B, Srigley J, Varma M, Tsuzuki T, Egevad L (June 2021). "Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts". Annals of Diagnostic Pathology. 52: 151733. doi:10.1016/j.anndiagpath.2021.151733. PMID   33780691. S2CID   232420551.
  6. ↑ Skálová A, Hyrcza MD, Leivo I (March 2022). "Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Salivary Glands". Head and Neck Pathology. 16 (1): 40–53. doi:10.1007/s12105-022-01420-1. PMC   9018948 . PMID   35312980.
  7. ↑ Davis A, Khachemoune A (February 2022). "Reappraisal and literature review of primary cutaneous cribriform apocrine carcinoma". Archives of Dermatological Research. 315 (1): 7–16. doi:10.1007/s00403-022-02323-5. PMID   35124722. S2CID   246558023.
  8. ↑ Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simões M, Tallini G, Mete O (March 2022). "Overview of the 2022 WHO Classification of Thyroid Neoplasms". Endocrine Pathology. 33 (1): 27–63. doi:10.1007/s12022-022-09707-3. PMID   35288841. S2CID   247440666.
  9. ↑ Taylor AS, Liu N, Fang JM, Panarelli N, Zhao L, Cheng J, Gopal P, Hammer S, Sun J, Appelman H, Westerhoff M (July 2022). "Cribriform colon cancer: a morphological growth pattern associated with extramural venous invasion, nodal metastases and microsatellite stability". Journal of Clinical Pathology. 75 (7): 483–487. doi:10.1136/jclinpath-2021-207485. PMID   33782192. S2CID   232420622.
  10. ↑ Carraro DM, Elias EV, Andrade VP (February 2014). "Ductal carcinoma in situ of the breast: morphological and molecular features implicated in progression". Bioscience Reports. 34 (1). doi:10.1042/BSR20130077. PMC   3894794 . PMID   27919043.
  11. 1 2 3 4 5 Branca G, Ieni A, Barresi V, Tuccari G, Caruso RA (March 2017). "An Updated Review of Cribriform Carcinomas with Emphasis on Histopathological Diagnosis and Prognostic Significance". Oncology Reviews. 11 (1): 317. doi:10.4081/oncol.2017.317. PMC   5364999 . PMID   28382188.
  12. 1 2 3 4 5 6 7 8 9 Liu J, Zheng X, Han Z, Lin S, Han H, Xu C (February 2021). "Clinical characteristics and overall survival prognostic nomogram for invasive cribriform carcinoma of breast: a SEER population-based analysis". BMC Cancer. 21 (1): 168. doi: 10.1186/s12885-021-07895-5 . PMC   7887783 . PMID   33593316.
  13. 1 2 3 4 5 6 Cong Y, Qiao G, Zou H, Lin J, Wang X, Li X, Li Y, Zhu S (April 2015). "Invasive cribriform carcinoma of the breast: A report of nine cases and a review of the literature". Oncology Letters. 9 (4): 1753–1758. doi:10.3892/ol.2015.2972. PMC   4356388 . PMID   25789036.
  14. 1 2 3 4 5 6 Zhang W, Zhang T, Lin Z, Zhang X, Liu F, Wang Y, Liu H, Yang Y, Niu Y (2013). "Invasive cribriform carcinoma in a Chinese population: comparison with low-grade invasive ductal carcinoma-not otherwise specified". International Journal of Clinical and Experimental Pathology. 6 (3): 445–57. PMC   3563205 . PMID   23412348.
  15. ↑ Liu XY, Jiang YZ, Liu YR, Zuo WJ, Shao ZM (August 2015). "Clinicopathological Characteristics and Survival Outcomes of Invasive Cribriform Carcinoma of Breast: A SEER Population-Based Study". Medicine. 94 (31): e1309. doi:10.1097/MD.0000000000001309. PMC   4616584 . PMID   26252312.
  16. ↑ Yılmaz TU, Trabzonlu L, Güler SA, Baran MA, Pösteki G, Erçin C, Utkan Z (January 2018). "Characteristics of Special Type Breast Tumors in Our Center". European Journal of Breast Health. 14 (1): 17–22. doi:10.5152/ejbh.2017.3219. PMC   5758058 . PMID   29322114.
  17. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Demir S, Sezgin G, Sari AA, Kucukzeybek BB, Yigit S, Etit D, Yazici A, Kucukzeybek Y (October 2021). "Clinicopathological analysis of invasive cribriform carcinoma of the breast, with review of the literature". Annals of Diagnostic Pathology. 54: 151794. doi:10.1016/j.anndiagpath.2021.151794. PMID   34325338.
  18. 1 2 Aghahowa ME, Salu IK, Ezike KN, Bassey OS, Umar MU, Etim OA, Okwudire-Ejeh IA (2018). "Advanced, Recurrent, Invasive Cribiform Carcinoma of the Breast in a 17-Year-Old Male: A Case Report". Journal of the West African College of Surgeons. 8 (4): 114–124. PMC   7861190 . PMID   33553054.
  19. 1 2 3 4 5 6 Zhang W, Lin Z, Zhang T, Liu F, Niu Y (November 2012). "A pure invasive cribriform carcinoma of the breast with bone metastasis if untreated for thirteen years: a case report and literature review". World Journal of Surgical Oncology. 10: 251. doi: 10.1186/1477-7819-10-251 . PMC   3523063 . PMID   23167837.
  20. ↑ Liu B, Newburg DS (August 2013). "Human milk glycoproteins protect infants against human pathogens". Breastfeeding Medicine. 8 (4): 354–62. doi:10.1089/bfm.2013.0016. PMC   3725943 . PMID   23697737.
  21. ↑ Moorman AM, Vink R, Rutgers EJ, Kouwenhoven EA (November 2020). "Incidence, clinical features, and outcomes of special types in breast cancer in a single institution population". The Breast Journal. 26 (11): 2163–2169. doi: 10.1111/tbj.14069 . PMID   33022133. S2CID   222184203.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.